Volume 11 Issue 1
Jan.  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(1): 47-53
Wang Guoying. New progress on liver transplantation for liver cancer: 2019 ILTS annual collection[J]. ORGAN TRANSPLANTATION, 2020, 11(1): 47-53. doi: 10.3969/j.issn.1674-7445.2020.01.007
Citation: Wang Guoying. New progress on liver transplantation for liver cancer: 2019 ILTS annual collection[J]. ORGAN TRANSPLANTATION, 2020, 11(1): 47-53. doi: 10.3969/j.issn.1674-7445.2020.01.007
shu

New progress on liver transplantation for liver cancer: 2019 ILTS annual collection

doi: 10.3969/j.issn.1674-7445.2020.01.007

  • Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

  • Received Date: 2019-11-03
    Available Online: 2021-01-19
  • Publish Date: 2020-01-15
    Abstract
  • The 25th Annual Congress of International Liver Transplantation Society (ILTS) was held from May 15 to 18, 2019 in Toronto, Canada. Focusing on the special topic of liver transplantation for liver cancer, down-staging liver cancer and bridging therapy before liver transplantation, prediction of liver cancer recurrence after liver transplantation, individualized immunosuppressive scheme, prevention and treatment of liver cancer recurrence after liver transplantation were summarized in this article. In addition, the literatures published in recent two years related to the research progress were reviewed.

     

    • FullText(HTML)
  • loading
    • References(33)
  • [1]
    HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380. DOI: 10.1002/hep.29086.
    [2]
    EILARD MS, ANDERSSON M, NAREDI P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1):568. DOI: 10.1186/s12885-019-5760-8.
    [3]
    HALAZUN KJ, NAJJAR M, ABDELMESSIH RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new moral to the story[J]. Ann Surg, 2017, 265(3):557-564. DOI: 10.1097/SLA.0000000000001966.
    [4]
    LAI Q, VITALE A, IESARI S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl, 2019, 25(7):1023-1033. DOI: 10.1002/lt.25492.
    [5]
    MAGGIORE U, PASCUAL J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients[J]. Adv Chronic Kidney Dis, 2016, 23(5):312-316. DOI: 10.1053/j.ackd.2016.08.002.
    [6]
    NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2019, DOI: 10.1111/ajt.15617 [Epubahead of print].
    [7]
    KHALAILEH A, KHOURY T, HARKROSH S, et al. Multiplication product of model for end-stage liver disease and donor risk index as predictive models of survival after liver transplantation[J]. Eur J Gastroenterol Hepatol, 2019, 31(9):1116-1120. DOI: 10.1097/MEG.0000000000001396.
    [8]
    MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol, 2017, 3(4):493-500. DOI: 10.1001/jamaoncol.2016.5116.
    [9]
    MAZZAFERRO V, SPOSITO C, ZHOU J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1):128-139. DOI: 10.1053/j.gastro.2017.09.025.
    [10]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会.中国肝癌肝移植临床实践指南(2018版) [J/CD].中华移植杂志(电子版), 2018, 12(4):145-150. DOI: 10.3877/cma.j.issn.1674-3903.2018.04.001.

    Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physician of Chinese Medical Doctor Association. Clinical practice guideline for liver transplantation of liver cancer in China [J/CD]. Chin J Transplant(Electr Vers), 2018, 12(4):145-150. DOI: 10.3877/cma.j.issn.1674-3903.2018.04.001.
    [11]
    GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with Meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10):1260-1273. DOI: 10.1111/apt.15253.
    [12]
    RODRÍGUEZ-PERÁLVAREZ M, GUERRERO M, BARRERA L, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplantation, 2018, 102(12):2056-2064. DOI: 10.1097/TP.0000000000002270.
    [13]
    JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7):932-945. DOI: 10.1002/lt.25191.
    [14]
    IAVARONE M, INVERNIZZI F, CZAUDERNA C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation[J]. Am J Transplant, 2019, 19(11):3176-3184. DOI: 10.1111/ajt.15551.
    [15]
    LIPSON EJ, BAGNASCO SM, MOORE J JR, et al. Tumor regression and allograft rejection after administration of anti-PD-1[J]. N Engl J Med, 2016, 374(9):896-898. DOI: 10.1056/NEJMc1509268.
    [16]
    汪国营, 唐晖, 张英才, 等.程序性死亡受体(PD)-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎:附1例报告[J].器官移植, 2016, 7(1):44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008.

    WANG GY, TANG H, ZHANG YC, et al. Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report[J]. Organ Transplant, 2016, 7(1):44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008.
    [17]
    FISHER J, ZEITOUNI N, FAN W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2019, DOI: 10.1016/j.jaad.2019.07.005[Epubahead of print].
    [18]
    ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1):106. DOI: 10.1186/s40425-019-0585-1.
    [19]
    DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?[J]. Curr Opin Oncol, 2019, 31(2):54-64. DOI: 10.1097/CCO.0000000000000505.
    [20]
    HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463. DOI: 10.1177/1758835919843463.
    [21]
    MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7):970-973. DOI: 10.1177/2050640618774631.
    [22]
    DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6):1054-1062. DOI: 10.21037/jgo.2018.07.05.
    [23]
    RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?[J]. Hepatology, 2018, 67(3):1166-1168. DOI: 10.1002/hep.29575.
    [24]
    CHEN JA, ESTEGHAMAT N, KIM EJ, et al. PD-1 blockade in a liver transplant recipient with microsatellite unstable metastatic colorectal cancer and hepatic impairment[J]. J Natl Compr Canc Netw, 2019, 17(9):1026-1030. DOI: 10.6004/jnccn.2019.7328.
    [25]
    BIONDANI P, DE MARTIN E, SAMUEL D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient[J]. Ann Oncol, 2018, 29(1):286-287. DOI: 10.1093/annonc/mdx548.
    [26]
    MEHTA N, DODGE JL, GRAB JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time[J]. Hepatology, 2019, DOI: 10.1002/hep.30879 [Epubahead of print].
    [27]
    VERNA EC, PATEL YA, AGGARWAL A, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant[J]. Am J Transplant, 2019, DOI: 10.1111/ajt.15697[Epubahead of print].
    [28]
    KORNBERG A, WITT U, SCHERNHAMMER M, et al. The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma[J]. J Surg Oncol, 2019, 120(7):1126-1136. DOI: 10.1002/jso.25721.
    [29]
    MCVEY JC, SASAKI K, FIRL DJ, et al. Prognostication of inflammatory cells in liver transplantation: is the waitlist neutrophil-to-lymphocyte ratio really predictive of tumor biology?[J]. Clin Transplant, 2019, 26:e13743. DOI: 10.1111/ctr.13743.
    [30]
    GRĄT K, PACHO R, GRĄT M, et al. Impact of body composition on the risk of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Med, 2019, 8(10): E1672. DOI: 10.3390/jcm8101672.
    [31]
    COSTENTIN CE, BABABEKOV YJ, ZHU AX, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation?[J]. Hepatology, 2019, 69(3):1324-1336. DOI: 10.1002/hep.30278.
    [32]
    HONG SK, LEE KW, YOON KC, et al. Different prognostic factors and strategies for early and late recurrence after adult living donor liver transplantation for hepatocellular carcinoma[J]. Clin Transplant, 2019, 33(10):e13703. DOI: 10.1111/ctr.13703.
    [33]
    ZHUANG L, MOU HB, YU LF, et al. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2019, DOI: 10.1016/j.hbpd.2019.09.011[Epubahead of print].
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (253) PDF downloads(26) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return